Time to onset of clinically relevant hyponatremia under treatment with oxcarbazepine

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036430

Enrollment

Registered

2025-03-19

Start date

2025-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E87.1 G40

Interventions

Group 1: Retrospective analysis of all patients who developed hyponatremia during oxcarbazepine therapy between 2020 and 2025

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Initiation of oxcarbazepine treatment under inpatient conditions. Normal serum sodium concentration of at least 135 mmol/L prior to initiation of oxcarbazepine treatment.

Exclusion criteria

Exclusion criteria: Concomitant medication with drugs that could potentially lower serum sodium. Additional medical conditions that could affect serum sodium, e.g., syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Design outcomes

Primary

Measure	Time frame
Time to decrease in serum sodium below 135 mmol/L	—

Secondary

Measure	Time frame
Symptoms of hyponatremia	—

Countries

Germany

Contacts

Public ContactBernhard J. Steinhoff

Epilepsiezentrum Kork

StudienabteilungKorkERW@Diakonie-Kork.de+497851842181

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026